Stifel on Outset Medical Inc. (OM): 'At Last, A Big Sigh of Relief As FDA Terms Tablo Catch-Up Filing As “Substantially-Equivalent”'

August 1, 2022 8:57 AM

Stifel analyst Rick Wise reiterated a Buy rating and $24.00 price target on Outset Medical Inc. (NASDAQ: OM).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Stifel on Outset Medical Inc. (OM): 'At Last, A Big Sigh of Relief As FDA Terms Tablo Catch-Up Filing As “Substantially-Equivalent”'

Categories

Next Articles